SecBot SecBot
SECBOTREPLAY Home › Report › ARQT

ARQT · Arcutis Biotherapeutics filed an 8-K reporting the results of its 2026…

Arcutis Biotherapeutics, Inc. · 8-K filed Jun 9, 2026 at 16:05 ET

At the news

NEUTRALIMPACT 2/10

8-K filed Jun 9, 2026 at 16:05 ET

Arcutis Biotherapeutics filed an 8-K reporting the results of its 2026 Annual Meeting of Stockholders, where all three proposals were approved, including the election of three Class III directors, ratification of Ernst & Young as independent auditor, and non-binding advisory approval of executive compensation. Separately, the Board approved an amended and restated Non-Employee Director Compensation Program, effective June 5, 2026, which sets annual cash retainers (e.g., $50,000 base for non-employee directors) and equity awards (initial option up to $350,000 grant date fair value, annual awards of ~$350,000 split 65% options / 35% RSUs). This is a routine governance filing with no material financial impact.

  • All three proposals at the 2026 Annual Meeting were approved by stockholders.
  • Three Class III directors elected: Patrick J. Heron, Neha Krishnamohan, Todd Franklin Watanabe.
  • Ratification of Ernst & Young LLP as independent auditor for fiscal year 2026 approved (107,867,442 for, 15,748 against, 261,364 abstentions).
  • Non-binding advisory approval of named executive officer compensation passed (88,728,269 for, 3,723,408 against, 824,860 abstentions, 14,868,017 broker non-votes).

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access